Zhengye Biotechnology Holding Ltd
Datakwaliteit: 100%
ZYBT
Nasdaq
Manufacturing
Chemicals
€ 1,06
▲
€ 0,07
(7,07%)
Marktkapitalisatie: 46,44 M
Prijs
€ 0,98
Marktkapitalisatie
46,44 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
ROE of 3,98% is below average
Debt/Equity of 0,30 — conservative balance sheet
Generating 3,76 M in free cash flow
Cash machine — converts 242,71% of earnings into free cash flow
Capital efficient — spends only 7,29% of revenue on capex
ROIC of 3,56% — low return on invested capital
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
3,98%
Boven sectorgemiddelde (-53,47%)
ROIC3,56%
Net Margin6,07%
Op. Margin8,82%
Veiligheid
Debt / Equity
0,30
Onder sectorgemiddelde (0,30)
Current Ratio1,31
Interest Coverage4,06
Waardering
PE (TTM)
29,96
Boven sectorgemiddelde (-1,48)
P/B Ratio1,19
EV/EBITDA10,02
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 30,0 | -1,5 |
| P/B | 1,2 | 1,6 |
| ROE % | 4,0 | -53,5 |
| Net Margin % | 6,1 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | 0,3 | 0,3 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
Geen toekomstige schattingen beschikbaar
No quarterly estimates available
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 25,53 M | Net Income (TTM) | 1,55 M |
| ROE | 3,98% | ROA | 2,29% |
| Gross Margin | 48,99% | Operating Margin | 8,82% |
| Net Margin | 6,07% | Free Cash Flow (TTM) | 3,76 M |
| ROIC | 3,56% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,30 | Current Ratio | 1,31 |
| Interest Coverage | 4,06 | Asset Turnover | 0,38 |
| Working Capital | 5,71 M | Tangible Book Value | 36,87 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 29,96 | Forward P/E | N/A |
| P/B Ratio | 1,19 | P/S Ratio | 1,82 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 10,02 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 8,10% | ||
| Market Cap | 46,44 M | Enterprise Value | 55,74 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,03 | Revenue / Share | 0,54 |
| FCF / Share | 0,08 | OCF / Share | 0,12 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 7,29% | FCF Conversion | 242,71% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 |
|---|---|
| Revenue | 25,53 M |
| Net Income | 1,55 M |
| EPS (Diluted) | 0,03 |
| Gross Profit | 12,51 M |
| Operating Income | 2,25 M |
| EBITDA | — |
| R&D Expenses | 1,75 M |
| SG&A Expenses | — |
| D&A | 3,31 M |
| Interest Expense | 554.000,0 |
| Income Tax | 127.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 |
|---|---|
| Total Assets | 67,58 M |
| Total Liabilities | 19,28 M |
| Shareholders' Equity | 38,90 M |
| Total Debt | 11,84 M |
| Cash & Equivalents | 2,55 M |
| Current Assets | 24,33 M |
| Current Liabilities | 18,62 M |
{"event":"ticker_viewed","properties":{"ticker":"ZYBT","listing_kind":"stock","pathname":"/stocks/zybt","exchange":"Nasdaq","country":"US"}}